Table 4. Mutations associated with isoniazid, rifampicin, fluoroquinolones, and second-line injectable drug-resistant M. tuberculosis Complex isolates.
| Anti-TB drugs | No. of resistant isolates | The pattern of gene mutations wild type/mutant | Amino acid change | Frequency (%) |
|---|---|---|---|---|
| Isoniazid | 26 | ΔkatG WT/ katG MUT1 | S315T1 | 20 (76.9) |
| ΔkatG WT/katG MUT2 | S315T2 | 2 (7.7) | ||
| ΔkatG WT/ND | - | 1 (3.8) | ||
| ΔinhA WT/inhA MUT1 | C15T | 3 (11.5) | ||
| Rifampicin | 19 | ΔrpoB WT8/rpoB MUT3 | S531L | 10 (52.6) |
| ΔrpoB WT7/rpoB MUT2A | H526Y | 3 (15.8) | ||
| ΔrpoB WT3 and rpoBWT4/rpoB MUT1 | D516V | 2 (10.5) | ||
| ΔrpoB WT7/ND | - | 2 (10.5) | ||
| ΔrpoB WT3 and rpoBWT4/ ND | - | 1 (5.3) | ||
| No missing rpoB WT/rpoBMUT3 | - | 1 (5.3) | ||
| Fluoroquinolones and second-line injectable drugs | 2 | ΔgyrA WT2/gyrA MUT1 | - | 1 (50) |
| ΔgyrA WT1 and gyrA WT3/ ND and Δrrs WT1/ ND | G88A/G88C | 1 (50) |
Δ, deletion; MUT, mutant; ND, no mutation detected at the mutant probe; “-”, not identified.